729 related articles for article (PubMed ID: 28494972)
21. The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer's Disease.
Yin X; Qiu Y; Zhao C; Zhou Z; Bao J; Qian W
Med Sci Monit; 2021 Sep; 27():e933084. PubMed ID: 34471085
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.
Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N
Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446
[TBL] [Abstract][Full Text] [Related]
23. Role of Amyloid-β and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade.
Gulisano W; Maugeri D; Baltrons MA; Fà M; Amato A; Palmeri A; D'Adamio L; Grassi C; Devanand DP; Honig LS; Puzzo D; Arancio O
J Alzheimers Dis; 2018; 64(s1):S611-S631. PubMed ID: 29865055
[TBL] [Abstract][Full Text] [Related]
24. Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.
Xin SH; Tan L; Cao X; Yu JT; Tan L
Neurotox Res; 2018 Oct; 34(3):733-748. PubMed ID: 29626319
[TBL] [Abstract][Full Text] [Related]
25. Leptin prevents aberrant targeting of tau to hippocampal synapses via PI 3 kinase driven inhibition of GSK3β.
Hamilton K; Morrow K; Markantoni E; Harvey J
J Neurochem; 2023 Nov; 167(4):520-537. PubMed ID: 37822142
[TBL] [Abstract][Full Text] [Related]
26. Synaptic basis of Alzheimer's disease: Focus on synaptic amyloid beta, P-tau and mitochondria.
John A; Reddy PH
Ageing Res Rev; 2021 Jan; 65():101208. PubMed ID: 33157321
[TBL] [Abstract][Full Text] [Related]
27. SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer's Disease.
Trujillo-Estrada L; Vanderklish PW; Nguyen MMT; Kuang RR; Nguyen C; Huynh E; da Cunha C; Javonillo DI; Forner S; Martini AC; Sarraf ST; Simmon VF; Baglietto-Vargas D; LaFerla FM
Neurotherapeutics; 2021 Oct; 18(4):2468-2483. PubMed ID: 34738197
[TBL] [Abstract][Full Text] [Related]
28. Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease.
Zumkehr J; Rodriguez-Ortiz CJ; Cheng D; Kieu Z; Wai T; Hawkins C; Kilian J; Lim SL; Medeiros R; Kitazawa M
Neurobiol Aging; 2015 Jul; 36(7):2260-2271. PubMed ID: 25964214
[TBL] [Abstract][Full Text] [Related]
29. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease.
Tu S; Okamoto S; Lipton SA; Xu H
Mol Neurodegener; 2014 Nov; 9():48. PubMed ID: 25394486
[TBL] [Abstract][Full Text] [Related]
30. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
Xie Y; Tan Y; Zheng Y; Du X; Liu Q
J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
[TBL] [Abstract][Full Text] [Related]
31. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
[TBL] [Abstract][Full Text] [Related]
32. A role for tau at the synapse in Alzheimer's disease pathogenesis.
Pooler AM; Noble W; Hanger DP
Neuropharmacology; 2014 Jan; 76 Pt A():1-8. PubMed ID: 24076336
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneous Association of Alzheimer's Disease-Linked Amyloid-β and Amyloid-β Protein Precursor with Synapses.
Willén K; Sroka A; Takahashi RH; Gouras GK
J Alzheimers Dis; 2017; 60(2):511-524. PubMed ID: 28869466
[TBL] [Abstract][Full Text] [Related]
34. Dysfunction of NMDA receptors in Alzheimer's disease.
Zhang Y; Li P; Feng J; Wu M
Neurol Sci; 2016 Jul; 37(7):1039-47. PubMed ID: 26971324
[TBL] [Abstract][Full Text] [Related]
35. Beyond the sleep-amyloid interactions in Alzheimer's disease pathogenesis.
Ning S; Jorfi M
J Neurophysiol; 2019 Jul; 122(1):1-4. PubMed ID: 30864847
[TBL] [Abstract][Full Text] [Related]
36. Factors affecting the GABAergic synapse function in Alzheimer's disease: Focus on microRNAs.
Rivera J; Sharma B; Torres MM; Kumar S
Ageing Res Rev; 2023 Dec; 92():102123. PubMed ID: 37967653
[TBL] [Abstract][Full Text] [Related]
37. Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies.
Chen Y; Fu AKY; Ip NY
Pharmacol Ther; 2019 Mar; 195():186-198. PubMed ID: 30439458
[TBL] [Abstract][Full Text] [Related]
38. The role of pathological tau in synaptic dysfunction in Alzheimer's diseases.
Wu M; Zhang M; Yin X; Chen K; Hu Z; Zhou Q; Cao X; Chen Z; Liu D
Transl Neurodegener; 2021 Nov; 10(1):45. PubMed ID: 34753506
[TBL] [Abstract][Full Text] [Related]
39. Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression.
Hales CM; Dammer EB; Deng Q; Duong DM; Gearing M; Troncoso JC; Thambisetty M; Lah JJ; Shulman JM; Levey AI; Seyfried NT
Proteomics; 2016 Dec; 16(23):3042-3053. PubMed ID: 27718298
[TBL] [Abstract][Full Text] [Related]
40. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
Wu X; Kosaraju J; Zhou W; Tam KY
Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
